Ivabradine Aurobindo (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this inward sodium/potassium mixed current, the drug slows spontaneous depolarisation, resulting in a controlled reduction of heart rate without decreasing the strength of cardiac contraction.

The dose of Ivabradine Aurobindo is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate target, and tolerance. The prescriber will select the appropriate strength and dosing schedule according to current guidelines and individual patient factors.

Safety of ivabradine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers reduce heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and can lower blood pressure and contractility, making ivabradine a useful alternative when beta‑blockers are contraindicated or not tolerated.

Ivabradine Aurobindo tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Do not store in a refrigerator or freezer unless otherwise specified by the manufacturer.

Ivabradine Aurobindo is taken orally, usually with a glass of water. The tablet should be swallowed whole and not split, crushed, or chewed. Dosing times are typically aligned with the patient’s daily routine to maintain consistent heart‑rate control.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and persistent visual disturbances such as luminous phenomena. Patients should be monitored for these events, especially when initiating therapy or adjusting the dose.

Ivabradine Aurobindo is contraindicated in patients with severe hepatic impairment, sick sinus syndrome without a pacemaker, acute myocardial infarction, uncontrolled hypotension, or in those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of its excipients.